PIMECROLIMUS , Amlitelimab, Placebo, Amlitelimab, -, TACROLIMUS
EFC17561
Phase 3 small_molecule active
Quick answer
PIMECROLIMUS , Amlitelimab, Placebo, Amlitelimab, -, TACROLIMUS for Dermatitis atopic is a Phase 3 program (small_molecule) at Sanofi Pharma Bristol-Myers Squibb with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sanofi Pharma Bristol-Myers Squibb
- Indication
- Dermatitis atopic
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active